ATM

:   Ataxia Telangiectasia Mutated

NSCLC

:   non-small cell lung cancer

SNP

:   single nucleotide polymorphism

HR

:   hazard ratio

CI

:   confidence interval

DFS

:   disease-free survival

OS

:   overall survival

CT

:   Computed Tomography

GTV

:   gross tumor volume

PET

:   Positron Emission Tomography

PCR

:   polymerase chain reaction

MST

:   median survival time

INTRODUCTION
============

Lung cancer is one of the leading causes of cancer mortality worldwide, with nearly 2.1 million new lung cancer cases and 1.8 million lung cancer deaths reported in 2018 \[[@r1]\]. Lung cancer incidence in the United States has improved significantly in men, but remains high in the women \[[@r2]\]. In China, the incidence of lung cancer has increased by 26.9% annually, and the numbers of lung cancer patients have doubled every 10 to 15 years in the last 50 years \[[@r3]\]. Moreover, in the last three decades, the mortality rate of lung cancer has increased by 465%, and replaced liver cancer as the most common malignant tumor in China \[[@r4]\]. The two main categories of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); NSCLC accounts for nearly 87% of all lung cancer cases, about 75% of which are diagnosed in the advanced stages with poor prognosis \[[@r5]\]. The 5-year survival rate of lung cancer patients is low and ranges from 5% to 31% \[[@r6], [@r7]\]. Radiotherapy is one of the main treatment modalities, especially for NSCLC patients that are not amenable for surgery \[[@r8]--[@r10]\]. The prognostic indicators in NSCLC patients include TNM stage \[[@r11]\], serum levels of tumor markers \[[@r12]\], tumor size \[[@r13]\], blood glucose levels, and treatment modalities \[[@r14], [@r15]\].

*Ataxia telangiectasia mutated* (*ATM*) gene is located on chromosome 11q 22.3 and encodes for the ATM protein that plays a significant role in DNA repair and cell cycle regulation \[[@r16], [@r17]\]. Previous case-control studies in Caucasian and Han Chinese populations have shown that several *ATM* gene polymorphisms are associated with increased risk of lung cancer \[[@r18]--[@r20]\]. However, their prognostic significance has not been studied in detail. Therefore, in this study, we analyzed the prognostic significance of four *ATM* SNPs in 720 Han Chinese NSCLC patients that received radiation or chemo-radiation therapy.

RESULTS
=======

General characteristics of the study population
-----------------------------------------------

We enrolled 720 NSCLC patients, including 335 males (46.5%) and 385 females (53.5%). We obtained their clinical and follow-up data to evaluate DFS and OS outcomes. Among these 720 patients, 497 (69.0%) were above 60 years, and 223 (31.0%) were ≤ 60 years of age. Furthermore, these patients included 370 (51.4%) smokers, 158 (21.9%) with squamous cell carcinoma, 358 (49.7%) with adenocarcinomas, and 204 (28.3%) with other cancer types. Moreover, 333 patients were diagnosed with stage IIIA and 387 with stage IIIB NSCLC. The cohort included 380 patients that received radiation therapy alone, whereas, the remaining 340 patients received chemoradiation therapy. While 357 patients received intensity-modulated radiation therapy (IMRT), 363 patients received three-dimensional conformal radiotherapy (3D-CRT) or another kind of radiotherapy. The median radiation dose received by this cohort was 65 Gy (419 patients received \< 65 Gy and 419 received ≥ 65 Gy). The four *ATM* SNPs analyzed in this study were rs664143 (GG, GA and AA genotypes at nucleotide positions 148, 381 and 191, respectively), rs664677 (TT, TC, and CC genotypes at nucleotide positions 265, 282, and 173, respectively), rs189037 (AA, AG, and GG genotypes at nucleotide positions 172, 283, and 165, respectively), and rs373759 (TT, TC, and CC genotypes at nucleotide positions 227, 294 and 199, respectively). The baseline clinical characteristics of the study population are listed in [Table 1](#t1){ref-type="table"}.

###### Relationship between clinical parameters and disease-free survival and overall survival in patients with NSCLC.

  --------------------- ------------------ --------------------------- ---------------------- ------------ ------------------ ----------------- ------------ ---------------- ------------ ------------------ ---------
  **Parameters**        **Category**       **Disease-free survival**   **Overall survival**                                                                                                                   
  **MST**               **Event/Total**    ***P^a^***                  **HR (95%CI)**         ***P^b^***   **MST**            **Event/Total**   ***P^a^***   **HR (95%CI)**   ***P^b^***                      
  Age                   ≤60                22.5                        116/223                0.851        1.00                                 42.8         84/223           0.445        1.00               
                        \>60               25.2                        267/497                             0.98 (0.79-1.22)   0.851             38.7         209/497                       1.10 (0.86-1.42)   0.445
  Gender                Female             28.9                        224/385                0.003        1.00                                 44.5         169/385                       1.00               
                        Male               24.1                        159/335                             1.36 (1.11-1.67)   0.003             30.3         124/335          0.118        1.20 (0.95-1.52)   0.119
  Smoking               No                 \-                          136/350                             1.00                                 57.9         110/350                       1.00               
                        Yes                21.0                        247/370                \<0.001      2.09 (1.70-2.58)   \<0.001           34.9         183/370          \<0.001      1.69 (1.33-2.15)   \<0.001
  Histology             SCC                24.5                        92/158                 0.130        1.00                                 52.9         57/158           0.058        1.00               
                        ADC                23.1                        191/358                             1.08 (0.84-1.38)   0.567             36.4         158/358                       1.40 (0.98-1.90)   0.068
                        Other              28.9                        100/204                             0.84 (0.63-1.11)   0.224             31.7         78/204                        1.02 (0.72-1.44)   0.910
  Stage                 IIIA               43.1                        142/333                \<0.001      1.00                                 52.9         119/333          0.005        1.00               
                        IIIB               22.7                        241/387                             1.67 (1.36-2.05)   \<0.001           36.7         174/387                       1.39 (1.12-1.76)   0.006
  Treatment             CRT                40.4                        149/340                \<0.001      1.00                                 52.7         122/340          0.013        1.00               
                        RT                 22.0                        234/380                             1.63 (1.33-2.01)   \<0.001           37.8         171/380                       1.34 (1.16-1.69)   0.014
  Radiation technique   IMRT               28.9                        170/357                0.006        1.00                                 42.7         136/357          0.378        1.00               
                        3D-CRT and other   24.7                        213/363                             1.33 (0.99-1.62)   0.056             41.1         157/363                       1.11 (0.88-1.40)   0.379
  Does                  ≥65Gy              29.6                        243/419                0.001        1.00                                 42.6         117/301          0.136        1.00               
                        \<65Gy             23.1                        140/301                             1.42 (1.15-1.75)   0.001             38.2         176/419                       1.29 (1.25-1.51)   0.013
  --------------------- ------------------ --------------------------- ---------------------- ------------ ------------------ ----------------- ------------ ---------------- ------------ ------------------ ---------

*P^a^*, Log-rank P; *P^b^*, univariate cox regression; MST, median survival time; RT, radiation therapy; CRT, chemoradiation therapy; SCC, squamous cell carcinoma.

ADC, adenocarcinoma; IMRT, Intensity Modulated Radiation Therapy; 3D-CRT, three-dimensional conformal radiotherapy.

Clinical characteristics and prognosis of NSCLC patients
--------------------------------------------------------

The median follow-up time was 36.4 months (range: 2.9--94.6 months) and 293 patients died before the last follow-up. The median DFS was 24.5 months, and 383 patients showed disease progression. Kaplan--Meier survival curve analysis showed that gender (*P* = 0.003), smoking (*P* \< 0.001), TNM stage (*P* \< 0.001), treatment modality (*P* \< 0.001), and radiation dose (P = 0.001) were significantly associated with DFS and OS. Patients with stage IIIB tumors showed significantly shorter DFS (HR = 1.67, 95%CI = 1.36--2.05, *P* \< 0.001) and OS (HR = 1.39, 95%CI = 1.12--1.76, *P* = 0.006) than stage IIIA lung cancer patients. The survival time was significantly longer for patients treated with chemoradiation therapy than those treated with radiation therapy alone (40.4 *vs.* 22.0 months, *P* \< 0.001). Moreover, patients treated with radiation therapy alone had worse survival outcomes than those treated with combination of chemo and radiation therapy (HR = 1.34, 95%CI = 1.16--1.69, *P* = 0.014). The OS rates for smoking NSCLC patients was significantly shorter than the non-smoking NSCLC patients (HR = 1.69, 95%CI = 1.69-1.33--2.15, *P* \< 0.001). Patients that received a radiation dose \< 65 Gy showed worse DFS rates (HR = 1.42, 95%CI = 1.15--1.75, *P* = 0.001) and OS (HR = 1.29, 95%CI = 1.25--1.51, *P* = 0.013) than NSCLC patients that received a radiation dose ≥ 65 Gy.

*ATM* SNPs and survival outcomes of NSCLC patients
--------------------------------------------------

Univariate analyses showed that two *ATM* SNPs, rs664143 and rs189037, as shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}, were significantly associated with DFS and OS, but, the other two *ATM* SNPs, rs664677 and rs373759, did not show any significant correlation with survival outcomes ([Table 2](#t2){ref-type="table"}).

###### Associations of ATM gene with DFS and OS in patients with NSCLC.

  ------------------------- --------------------------- ---------------------- ------------------------- ----------------- --------------- --------- ------------ ------------------------- ----------------- ---------
  **SNP**                   **Disease-free survival**   **Overall survival**                                                                                                                                  
  **Event/No.**             **MST**                     ***P^a^***             **Adjusted HR (95%CI)**   ***P^b^***        **Event/No.**   **MST**   ***P^a^***   **Adjusted HR (95%CI)**   ***P^b^***        
  rs664143                                                                                                                                                                                                    
  GG                        58/148                      33.4                   0.008                     1.00                              43/148    44.0         0.029                     1.00              
  GA                        219/381                     24.3                                             1.41(1.05-1.89)   0.023           166/381   37.8                                   1.22(1.17-1.72)   0.014
  AA                        106/191                     22.7                                             1.38(1.01-1.91)   0.034           84/191    33.6                                   1.40(1.23-2.04)   0.024
  Trend                                                                                                                                                                                                       
  GG                        58/148                      33.4                   0.002                     1.00                              43/148    44.0         0.023                     1.00              
  GA+AA                     325/571                     23.8                                             1.40(1.05-1.86)   0.021           250/572   35.9                                   1.28(1.12-1.78)   0.040
  GG+GA                     277/528                     26.0                   0.248                     1.00                              209/529   36.1         0.049                     1.00              
  AA                        106/191                     22.7                                             1.06(0.85-1.33)   0.596           84/191    33.6                                   1.20(0.93-1.55)   0.164
  rs664677                                                                                                                                                                                                    
  TT                        142/265                     25.5                   0.929                     1.00                              115/265   42.7         0.670                     1.00              
  TC                        152/282                     24.1                                             1.11(0.88-1.40)   0.379           116/282   38.7                                   1.13(0.87-1.47)   0.348
  CC                        89/173                      28.0                                             1.02(0.78-1.33)   0.874           62/173    32.7                                   0.97(0.71-1.32)   0.852
  Trend                                                                                                                                                                                                       
  TT                        160/259                     25.5                   0.928                     1.00                              115/265   42.7         0.888                     1.00              
  TC+CC                     241/455                     24.5                                             0.97(0.77-1.22)   0.777           178/455   35.7                                   1.07(0.85-1.36)   0.575
  TT+TC                     294/547                     28.0                   0.766                     1.00                              231/547   33.4         0.465                     1.00              
  CC                        48/79                       24.5                                             0.88(0.67-1.15)   0.344           62/173    32.7                                   0.91(0.69-1.21)   0.531
  rs189037                                                                                                                                                                                                    
  AA                        94/172                      31.0                   0.007                     1.00                              56/172    43.5         \<0.001                   1.00              
  AG                        221/383                     23.8                                             1.48(1.18-2.03)   0.014           192/383   34.9                                   1.76(1.21-2.45)   0.001
  GG                        68/165                      24.5                                             1.32(1.17-1.91)   0.012           45/165    33.5                                   1.23(1.13-1.83)   0.029
                                                                                                                                                                                                              
  Trend                                                                                                                                                                                                       
  AA                        94/172                      31.0                   0.004                     1.000                             53/172    43.5         0.001                     1.00              
  AG+GG                     289/548                     24.1                                             1.44(1.06-1.95)   0.019           237/548   36.0                                   1.16(1.17-2.21)   0.004
  AA+AG                     315/555                     24.7                   0.523                     1.00                              248/555   37.8         0.145                     1.00              
  GG                        68/165                      24.5                                             0.98(0.75-1.29)   0.906           45/165    33.5                                   0.80(0.60-1.08)   0.141
  rs373759                                                                                                                                                                                                    
  TT                        122/227                     25.2                   0.508                     1.00                              103/227   35.6         0.103                     1.00              
  TC                        157/294                     23.1                                             1.14(0.90-1.45)   0.286           117/294   34.9                                   1.08(0.82-1.41)   0.590
  CC                        104/199                     29.0                                             0.99(0.76-1.30)   0.968           73/199    44.9                                   0.81(0.60-1.10)   0.814
  Trend                                                                                                                                                                                                       
  TT                        122/227                     25.2                   0.908                     1.00                              103/227   35.6         0.489                     1.00              
  TC+CC                     261/493                     24.5                                             1.07(0.87-1.34)   0.496           190/493   41.8                                   0.96(0.75-1.22)   0.739
  TT+TC                     279/521                     29.0                   0.324                     1.00                              220/521   35.4         0.035                     1.00              
  CC                        104/199                     24.7                                             0.92(0.73-1.17)   0.505           73/199    44.9                                   0.78(0.60-1.02)   0.074
  Number of risk allele\*                                                                                                                                                                                     
  0                         14/35                       33.6                   \<0.001                   1.00                              7/35      \-           0.002                     1.00              
  1                         85/155                      24.5                                             1.37(0.78-2.41)   0.279           58/155    52.9                                   1.59(0.73-3.49)   0.244
  2                         164/310                     26.7                                             1.30(0.75-2.42)   0.138           137/310   36.9                                   1.82(0.85-3.89)   0.122
  3                         106/180                     \-                                               1.53(1.13-2.66)   0.004           81/180    35.5                                   2.01(1.13-4.35)   0.017
  4                         14/40                       19.7                                             2.91(1.43-3.93)   \<0.001         10/40     28.6                                   1.42(1.22-2.95)   \<0.001
  ------------------------- --------------------------- ---------------------- ------------------------- ----------------- --------------- --------- ------------ ------------------------- ----------------- ---------

*P^a^*, Log-rank P; *P^b^*, cox regression for adjusting age, gender, smoking, histology, stage, treatment, radiation technique, does; MST, median survival time.

Trend: the prognosis showed an increased or decreased changed with the number of risk allele.

\*Number of risk allele: For rs664143(A) and rs189037(G): 0(GG+AA), 1(GG+AG, GA+AA), 3(AA+AG, GA+GG), 4(AA+GG).

The patients with *ATM* rs664143 AA and GA genotypes showed significantly shorter DFS (median survival time or MST (month): 22.7 vs. 24.3 *vs.* 33.4; *P* = 0.008; [Figure 1A](#f1){ref-type="fig"}) and OS (MST: 33.6 vs. 37.8 *vs.* 52.9 months; *P* = 0.029; [Figure 1C](#f1){ref-type="fig"}) than patients with the rs664143 GG genotype. After adjusting for clinical parameters, Cox regression analysis showed that patients with *ATM* rs664143 AA or GA genotypes showed worse survival outcomes than those with the rs664143 GG phenotype (AA vs. GG, HR: 1.38, 95%CI = 1.01-1.19, *P* = 0.034; GA vs. GG, 1.41, 95%CI = 1.05--1.89, *P* = 0.023). The rs664143 G allele showed dominant effect than the rs664143 A allele (GA/AA *vs.* GG: *P* = 0.002 for DFS, [Figure 1B](#f1){ref-type="fig"}; *P* = 0.023 for OS, [Figure 1D](#f1){ref-type="fig"}). According to multivariate Cox regression analysis, patients with rs664143 GA and rs664143 AA genotypes showed worse DFS (HR = 1.40, 95%CI = 1.05--1.86, *P* = 0.021) and OS (HR = 1.28, 95%CI = 1.12--1.78, *P* = 0.040) than those with the rs664143 GG phenotype. Patients with the *ATM* rs189037 GG and rs189037 AG genotypes showed significantly shorter DFS (MST: 24.5 vs. 23.8 vs. 31.0 months, *P* = 0.007, [Figure 2A](#f2){ref-type="fig"}) and OS (MST: 33.5 vs. 34.9 vs. 43.5, *P* \< 0.001, [Figure 2C](#f2){ref-type="fig"}) than those with the rs189037 AA genotype. After adjusting for clinical parameters, Cox regression analysis showed that patients with rs189037 GG or AG genotypes had worse DFS (GG *vs.* AA: HR = 1.32, 95%CI = 1.17--1.91, *P* = 0.012; AG *vs.* AA: HR = 1.48, 95%CI = 1.18--2.03, *P* = 0.014; [Table 2](#t2){ref-type="table"}) and OS (GG *vs.* AA: HR = 1.23, 95%CI = 1.13--1.83, P = 0.029; AG *vs.* AA: HR = 1.76, 95%CI = 1.21--2.45, *P* = 0.001) than those with rs189037 AA. The rs189037 G allele exhibited dominant effect than the rs189037 A allele (DFS: *P* = 0.004, [Figure 2B](#f2){ref-type="fig"}; OS: *P* = 0.001, [Figure 2D](#f2){ref-type="fig"}). Multivariate Cox regression analysis showed worse survival outcomes for patients with the rs189037 AG and GG genotypes than those with the rs189037 AA genotype (AG/GG *vs.* AA: DFS, HR = 1.44, 95%CI = 1.06--1.95, P = 0.019; OS, HR = 1.16, 95%CI = 1.16--1.17--2.21, *P* = 0.004; [Table 2](#t2){ref-type="table"}).

![Kaplan-Meier survival curve analysis shows disease-free survival (**A**) GG vs. GA vs. AA, (**B**) GA/AA vs. GG); and overall survival (**C**) GG vs. GA vs. AA, (**D**) GA/AA vs. GG, of NSCLC patients with ATM rs664143 genotypes that are treated with radiation or chemoradiation therapies.](aging-12-103094-g001){#f1}

![Kaplan-Meier survival curve analysis shows disease-free survival (**A**) AA vs. AG vs. GG, (**B**) AG/GG vs. AA; and overall survival (**C**) AA vs. AG vs. GG, (**D**) AG/GG vs. AA, of NSCLC patients with ATM rs189037 genotypes that are treated with radiation or chemoradiation therapies.](aging-12-103094-g002){#f2}

We also compared the association between the number of risk alleles (rs664143 and 189037) and survival outcomes, DFS and OS. The results showed that patients with the risk alleles were associated with worse DFS and OS compared to those without a risk allele ([Table 2](#t2){ref-type="table"}). As shown in [Table 3](#t3){ref-type="table"}, three SNPs (rs664143, rs664677, and rs373759) showed a prior false-positive probability of 0.1.

###### False-positive reports probability values for associations between gene and survival outcomes.

  ---------------- --------------------------- ----------------------- ----------------------- ---------------- ------------ ----------------------- ----------------------- ------- ------- ------- ----------- -------
  **SNP**          **Disease-free survival**   **Overall survival**                                                                                                                                              
  **HR (95%CI)**   ***P^b^***                  **Statistical power**   **Prior probability**   **HR (95%CI)**   ***P^b^***   **Statistical power**   **Prior probability**                                       
  **0.2**          **0.1**                     **0.01**                **0.2**                 **0.1**          **0.01**                                                                                         
  rs664143                                                                                                                                                                                                       
  GA vs. GG        1.41(1.05-1.89)             0.023                   0.741                   0.162            0.305        0.816                   1.22(1.17-1.72)         0.014   0.634   0.106   0.301       0.764
  AA vs. GG        1.38(1.01-1.91)             0.034                   0.720                   0.221            0.396        0.875                   1.40(1.23-2.04)         0.024   0.821   0.035   **0.074**   0.612
  GA/AA vs.GG      1.40(1.05-1.86)             0.021                   0.712                   0.111            0.198        0.801                   1.28(1.12-1.78)         0.040   0.903   0.161   0.254       0.821
  rs664677                                                                                                                                                                                                       
  TCvs.TT          1.11(0.88-1.40)             0.379                   0.701                   0.221            0.297        0.897                   1.13(0.87-1.47)         0.348   0.706   0.085   0.234       0.681
  CC vs.TT         1.02(0.78-1.33)             0.874                   0.623                   0.047            0.110        0.654                   0.97(0.71-1.32)         0.852   0.764   0.002   **0.097**   0.101
  TC/CCvs.TT       0.97(0.77-1.22)             0.777                   0.713                   0.051            **0.055**    0.635                   1.07(0.85-1.36)         0.575   0.934   0.001   0.216       0.024
  rs189037                                                                                                                                                                                                       
  GA vs. AA        1.48(1.08-2.03)             0.014                   0.769                   0.135            0.291        0.841                   1.76(1.21-2.45)         0.001   0.638   0.006   0.204       0.883
  GG vs. AA        1.32(1.17-1.91)             0.012                   0.812                   0.062            0.154        0.734                   1.23(1.13-1.83)         0.029   0.694   0.012   0.114       0.154
  GG/GA vs. AA     1.44(1.06-1.95)             0.019                   0.934                   0.216            0.221        0.886                   1.16(1.17-2.21)         0.004   0.824   0.031   0.310       0.135
  rs373759                                                                                                                                                                                                       
  TC vs. TT        1.14(0.90-1.45)             0.286                   0.685                   0.253            0.442        0.885                   1.08(0.82-1.41)         0.590   0.768   0.015   **0.014**   0.621
  CC vs. TT        0.99(0.76-1.30)             0.968                   0.821                   0.131            0.241        0.769                   0.81(0.60-1.10)         0.814   0.836   0.026   **0.004**   0.412
  TC/CC vs. TT     1.07(0.87-1.34)             0.496                   0.932                   0.468            0.468        0.908                   0.96(0.75-1.22)         0.739   0.931   0.018   **0.031**   0.232
  ---------------- --------------------------- ----------------------- ----------------------- ---------------- ------------ ----------------------- ----------------------- ------- ------- ------- ----------- -------

Subgroup analysis of *ATM* SNPs and NSCLC prognosis
---------------------------------------------------

We performed subgroup analysis with clinical factors such as smoking, histology, tumor stage, treatment, and radiation dose that are significantly associated with DFS and OS. The subgroup analysis showed that rs664143 and rs189037 were significantly associated with DFS and OS in both IIIA and IIIB stages ([Table 4](#t4){ref-type="table"} and [Table 5](#t5){ref-type="table"}). NSCLC patients with *ATM* rs664143 GA and AA genotypes showed worse DFS (stage IIIA: adjusted HR = 1.34, 95%CI = 1.18--2.05, P = 0.022; stage IIIB: adjusted HR = 1.52, 95%CI = 1.04--2.22, *P* = 0.030) and OS (stage IIIA: adjusted HR = 1.29, 95%CI = 1.18--2.09, *P* = 0.028; stage IIIB: adjusted HR = 1.51, 95%CI = 1.17--2.37, *P* = 0.021) than patients with the rs664143 GG genotype. Stage IIIA and IIIB NSCLC patients with rs189037 AG/GG genotypes showed significantly shorter median survival times than those with the rs189037 AA genotype (Stage IIIA: 39.0 vs. 58.6 months; stage IIIB: 27.1 vs. 43.7 months; [Table 4](#t4){ref-type="table"}). Cox regression analysis after adjustment showed shorter DFS and OS for the rs189037 AG/GG genotypes in than those with the rs189037 AA genotype in stage IIIA NSCLC (DFS: adjusted HR, 1.43; 95% CI = 1.31--2.22, *P* = 0.037; OS: adjusted HR, 1.62;(95%CI = 1.02--2.57, *P* = 0.042; [Table 5](#t5){ref-type="table"}) and stage IIIB NSCLC (DFS: adjusted HR,1.55; 95% CI = 1.05--2.38, *P* = 0.029; OS: adjusted HR, 1.69; 95% CI = 1.09--2.65, *P* = 0.020; [Table 5](#t5){ref-type="table"}). Moreover, patients with rs664143 and rs189037 SNPs that were smokers and received radiation therapy (RT) with a radiation dose \> 65 Gy showed worse survival outcomes than patients that were non-smokers and received chemo-radiation therapy (CRT) with a radiation dose ≤65 Gy, respectively ([Tables 4](#t4){ref-type="table"}, [5](#t5){ref-type="table"}). Furthermore, based on histology, the rs664143 and rs189037 gene polymorphisms were associated with DFS and OS among the patients with adenocarcinomas (ADC) as shown in [Tables 4](#t4){ref-type="table"}, [5](#t5){ref-type="table"}.

###### Subgroup multivariate analysis of clinical parameters for rs664143 and survival outcomes.

  ---------------- ----------------- -------------- --------------------------- ---------------------- --------------- ----------------- ------------ ------------------ ------------ ------- ----------------- -------
  **Parameters**   **Subgroup**      **Genotype**   **Disease-free survival**   **Overall survival**                                                                                                            
  **Event/No.**    **MST (month)**   ***P^a^***     **HR\* (95%CI)**            ***P^b^***             **Event/No.**   **MST (month)**   ***P^a^***   **HR\* (95%CI)**   ***P^b^***                             
  rs664143                                                                                                                                                                                                      
  Smoking          Yes               GG             34/62                       24.1                                   1.00                           27/62              36.4                 1.00              
                                     GA             145/207                     21.0                   0.204           1.46(0.99-2.15)   0.057        105/207            35.6         0.838   0.98(0.63-1.51)   0.930
                                     AA             68/101                      17.0                   0.013           1.65(1.32-2.07)   0.026        51/101             21.2         0.023   1.10(1.09-1.77)   0.037
                                     GA+AA          213/308                     19.5                   0.033           1.42(1.06-2.08)   0.047        156/308            29.4         0.014   1.31(1.27-1.53)   0.029
                   No                GG             24/86                       \-                                     1.00                           16/86              \-                   1.00              
                                     GA             74/174                      43.1                   0.058           1.31(1.12-2.11)   0.024        61/174             52.5         0.031   1.59(0.91-2.79)   0.103
                                     AA             38/90                       39.0                   0.022           1.36(1.14-2.29)   0.026        33/90              34.5         0.011   1.86(1.01-3.43)   0.047
                                     GA+AA          112/264                     39.0                   0.034           1.33(1.15-2.09)   0.022        94/264             44.5         0.015   1.67(1.27-2.87)   0.023
  Histology        SCC               GG             14/31                       \-                                     1.00                           7/31               \-                   1.00              
                                     GA             55/87                       22.7                   0.422           1.28(0.71-2.30)   0.416        34/87              62.8         0.455   1.32(0.59-2.99)   0.501
                                     AA             23/40                       23.5                   0.637           1.15(0.59-2.42)   0.674        16/40              36.7         0.367   1.59(0.65-3.87)   0.308
                                     GA+AA          78/127                      22.5                   0.461           1.24(0.70-2.19)   0.464        50/127             52.9                 1.40(0.63-3.09)   0.407
                   ADC               GG             30/80                       43.1                                   1.00                           24/80              \-                   1.00              
                                     GA             111/186                     20.7                   0.008           1.72(1.15-2.58)   0.008        92/186             35.9         0.049   1.57(0.99-2.45)   0.051
                                     AA             50/92                       22.5                   0.051           1.57(1.00-2.47)   0.052        42/92              39.2         0.055   1.65(1.01-2.73)   0.050
                                     GA+AA          160/278                                            0.009           1.67(1.31-2.47)   0.010        134/278            36.4                 1.59(1.03-2.46)   0.036
                   Other             GG             14/37                       30.8                                   1.00                           12/37              52.9                 1.00              
                                     GA             53/108                      28.9                   0.216           1.45(0.81-2.61)   0.216        40/108             44.5         0.595   1.20(0.63-2.28)   0.585
                                     AA             33/59                       23.4                   0.025           1.99(1.06-3.72)   0.032        26/59              35.5         0.070   1.82(0.91-3.60)   0.088
                                     GA+AA          86/167                      23.8                   0.091           1.62(0.92-2.85)   0.096        66/167             41.7                 1.38(0.75-2.56)   0.303
  Stage            IIIA              GG             27/84                       \-                                     1.00                           21/68              \-                   1.00              
                                     GA             76/168                      39.0                   0.114           1.34(1.16-2.09)   0.036        66/168             44.5         0.303   1.25(1.06-2.06)   0.037
                                     AA             39/81                       26.7                   0.106           1.35(1.08-2.22)   0.039        32/81              32.6         0.012   1.38(1.29-2.26)   0.014
                                     GA+AA          115/249                     39.0                   0.085           1.34(1.18-2.05)   0.014        98/249             37.5         0.008   1.29(1.18-2.09)   0.028
                   IIIB              GG             31/64                       28.9                                   1.00                           22/64              47.9                 1.00              
                                     GA             143/213                     22.0                   0.026           1.52(1.03-2.25)   0.034        100/213            55.6         0.127   1.44(0.91-2.29)   0.122
                                     AA             67/110                      19.7                   0.044           1.51(1.01-2.33)   0.043        52/110             24.9         0.038   1.68(1.02-2.78)   0.043
                                     GA+AA          210/323                     21.8                   0.020           1.52(1.04-2.22)   0.030        152/323            36.9         0.005   1.51(1.17-2.37)   0.021
  Treatment        RT                GG             31/65                       28.9                                   1.00                           22/65              47.9                 1.00              
                                     GA             139/208                     21.5                   0.033           1.50(1.02-2.22)   0.041        100/208            37.8         0.130   1.49(0.93-2.39)   0.096
                                     AA             64/107                      19.7                   0.066           1.45(1.39-2.23)   0.034        49/107             30.6         0.049   1.74(1.05-2.92)   0.034
                                     GA+AA          230/315                     21.2                   0.029           1.48(1.02-2.17)   0.041        149/315            35.9         0.021   1.57(1.21-2.48)   0.033
                   CRT               GG             27/83                       \-                                     1.00                           21/83              \-                   1.00              
                                     GA             80/173                      29.6                   0.100           1.31(0.80-2.16)   0.288        66/173             52.6         0.316   1.31(0.79-2.16)   0.288
                                     AA             42/84                       26.7                   0.036           1.51(1.27-2.62)   0.042        35/84              33.1         0.003   1.51(1.37-2.62)   0.014
                                     GA+AA          122/257                     29.6                   0.025           1.37(1.30-2.22)   0.017        101/257            43.5         0.019   1.37(1.25-2.22)   0.017
  Does             ≥65Gy             GG             32/76                       32.9                                   1.00                           23/76              \-                   1.00              
                                     GA             141/227                     23.1                   0.178           1.20(0.77-1.89)   0.423        101/227            40.4         0.695   1.19(0.71-2.01)   0.511
                                     AA             70/116                      17.0                   0.015           1.08(1.04-1.81)   0.025        52/116             29.2         0.016   1.21(1.07-2.17)   0.023
                                     GA+AA          211/343                     22.5                   0.023           1.16(1.05-1.80)   0.038        153/343            35.6         0.028   1.19(1.02-1.98)   0.036
                   \<65Gy            GG             26/72                       \-                                     1.00                           20/72              \-                   1.00              
                                     GA             78/154                      27.1                   0.009           1.62(1.09-2.42)   0.018        65/154             52.6         0.075   1.35(0.85-2.15)   0.203
                                     AA             36/75                       39.0                   0.003           1.69(1.09-2.61)   0.018        32/75              26.9         0.006   1.69(1.02-2.79)   0.042
                                     GA+AA          114/229                     29.4                   0.003           1.64(1.11-2.42)   0.012        97/229             33.7         0.024   1.45(1.39-2.28)   0.015
  ---------------- ----------------- -------------- --------------------------- ---------------------- --------------- ----------------- ------------ ------------------ ------------ ------- ----------------- -------

*P^a^*, Log-rank P; *P^b^*, multivariate cox regression; MST, median survival time; RT, radiation therapy; CRT, chemoradiation therapy.

###### Subgroup multivariate analysis of clinical parameters for 189037 and survival outcomes.

  ---------------- ----------------- -------------- --------------------------- ---------------------- --------------- ----------------- ------------ ----------------- ------------ ------- ----------------- -------
  **Parameters**   **Subgroup**      **Genotype**   **Disease-free survival**   **Overall survival**                                                                                                           
  **Event/No.**    **MST (month)**   ***P^a^***     **HR\*(95%CI)**             ***P^b^***             **Event/No.**   **MST (month)**   ***P^a^***   **HR\*(95%CI)**   ***P^b^***                             
  rs189037                                                                                                                                                                                                     
  Smoking          Yes               AA             24/71                       \-                                     1.00                           24/71             43.5                                   
                                     AG             121/214                     24.5                   0.014           1.61(0.97-2.66)   0.063        122/214           34.6         0.055   1.31(0.78-2.19)   0.309
                                     GG             43/85                       24.1                   0.039           1.67(1.06-2.60)   0.023        37/85             31.8         0.166   1.90(1.22-2.95)   0.004
                                     AG+GG          164/299                     24.5                   0.012           1.65(1.08-2.55)   0.022        159/299           32.1         0.010   1.71(1.11-2.63)   0.015
                   No                AA             26/94                       59.3                                   1.00                           21/94             \-                                     
                                     AG             70/169                      40.4                   0.184           1.40(1.09-2.0)    0.046        70/169            36.9         0.095   1.08(0.58-2.03)   0.800
                                     GG             25/87                       61.4                   0.017           1.05(1.01-1.83)   0.035        19/87             \-           0.027   1.78(1.09-2.90)   0.021
                                     AG+GG          95/256                      44.5                   0.015           1.29(1.13-2.00)   0.025        89/256            42.9         0.025   1.57(1.09-2.53)   0.045
  Histology        SCC               AA             28/45                       22.7                                   1.00                           14/45             73.5                 1.00              
                                     AG             49/80                       23.5                   0.836           0.62(0.33-1.16)   0.136        35/80             32.1         0.353   0.62(0.26-1.47)   0.276
                                     GG             15/33                       \-                     0.153           0.95(0.60-1.51)   0.832        8/33              \-           0.383   1.34(0.72-2.49)   0.354
                                     AG+GG          64/113                      22.7                   0.110           1.56(0.90-2.72)   0.115        43/113            38.1         0.067   1.98(0.64-4.190   0.073
                   ADC               AA             51/90                       22.5                                   1.00                           33/90             64.3                 1.00              
                                     AG             107/178                     20.7                   0.034           1.73(1.17-2.56)   0.006        102/178           31.5         0.089   0.65(0.38-1.11)   0.653
                                     GG             33/90                       43.1                   0.007           1.80(1.16-2.78)   0.009        23/90             58.4         0.000   1.46(0.99-2.170   0.057
                                     AG+GG          140/268                     21.5                   0.003           1.75(1.20-2.55)   0.003        125/268           34.6         0.002   2.01(1.29-3.13)   0.002
                   Other             AA             15/37                       33.3                                   1.00                           9/37              \-                   1.00              
                                     AG             65/125                      28.9                   0.271           0.92(0.55-1.51)   0.729        55/125            36.9         0.318   1.41(0.61-3.25)   0.426
                                     GG             20/42                       24.7                   0.154           0.64(0.33-1.25)   0.194        14/42             \-           0.995   1.80(0.89-3.65)   0.101
                                     AG+GG          85/167                      30.8                   0.505           0.85(0.52-1.38)   0.508        69/167            37.8         0.629   1.15(0.65-2.06)   0.631
  Stage            IIIA              AA             25/90                       58.6                                                                  22/90             \-                                     
                                     AG             77/162                      60.2                   0.051           1.09(0.62-1.91)   0.760        77/162            46.0         0.085   1.07(0.58-1.97)   0.832
                                     GG             25/81                       33.9                   0.037           1.59(1.01-2.50)   0.044        20/81             \-           0.012   1.85(1.15-2.97)   0.011
                                     AG+GG          102/243                     39.0                   0.012           1.43(1.31-2.22)   0.037        97/243            42.7         0.045   1.62(1.02-2.57)   0.042
                   IIIB              AA             25/75                       43.7                                   1.00                           23/75             44.3                 1.00              
                                     AG             114/221                     30.1                   0.032           1.59(1.02-2.48)   0.042        115/221           40.2         0.250   1.35(0.80-2.28)   0.267
                                     GG             43/91                       27.1                   0.037           1.45(1.28-2.39)   0.031        36/91             33.2         0.009   1.86(1.18-2.94)   0.008
                                     AG+GG          157/312                     27.1                   0.028           1.55(1.05-2.38)   0.029        151/312           33.7         0.019   1.69(1.09-2.65)   0.020
  Treatment        RT                AA             23/71                       \-                                     1.00                           22/71             48.4                 1.00              
                                     AG             110/218                     28.1                   0.027           1.54(0.98-2.43)   0.059        111/218           41.7         0.167   1.39(0.82-2.36)   0.221
                                     GG             44/91                       30.1                   0.019           1.49(1.19-2.48)   0.021        38/91             34.9         0.026   1.78(1.12-2.82)   0.015
                                     AG+GG          154/309                     29.0                   0.035           1.53(1.08-2.38)   0.049        149/309           34.9         0.036   1.65(1.06-2.59)   0.028
                   CRT               AA             27/94                       61.4                                   1.00                           23/94             \-                   1.00              
                                     AG             81/165                      33.6                   0.916           1.09(0.62-1.89)   0.772        81/165            35.1         0.869   0.99(0.53-1.85)   0.987
                                     GG             24/81                       \-                     0.029           1.58(1.02-2.46)   0.040        18/81             \-           0.003   1.87(1.17-2.97)   0.009
                                     AG+GG          105/246                     34.5                   0.039           1.43(1.02-2.20)   0.042        99/246            36.9         0.029   1.61(1.02-2.54)   0.041
  Does             ≥65Gy             AA             24/85                       \-                                     1.00                           23/85             48.4                 1.00              
                                     AG             113/232                     29.0                   0.069           1.17(0.80-1.73)   0.420        114/232           41.7         0.799   1.23(0.82-1.86)   0.311
                                     GG             46/102                      30.1                   0.014           1.31(1.23-1.32)   0.017        39/102            24.4         0.010   1.17(1.07-1.32)   0.020
                                     AG+GG          159/334                     29.2                   0.013           1.25(1.18-1.93)   0.021        153/334           34.9         0.006   1.47(1.29-2.36)   0.013
                   \<65Gy            AA             26/80                       59.3                                   1.00                           22/80             \-                   1.00              
                                     AG             78/151                      61.4                   0.016           1.68(1.02-2.76)   0.041        78/151            35.5         0.133   1.54(0.91-2.58)   0.104
                                     GG             22/70                       33.6                   0.039           1.70(1.09-2.66)   0..019       17/70             \-           0.007   1.98(1.26-3.11)   0.003
                                     AG+GG          100/221                     38.7                   0.014           1.70(1.10-2.61)   0.017        95/221            36.9         0.013   1.84(1.18-2.86)   0.007
  ---------------- ----------------- -------------- --------------------------- ---------------------- --------------- ----------------- ------------ ----------------- ------------ ------- ----------------- -------

*P^a^*, Log-rank P; *P^b^*, multivariate cox regression; MST, median survival time; RT, radiation therapy; CRT, chemoradiation therapy.

DISCUSSION
==========

In this study, we assessed the association between four *ATM* SNPs and the survival outcomes in NSCLC patients of Han Chinese origin who received radiation therapy alone or chemo-radiation therapy. We demonstrated that two SNPs, rs664143 and rs189037, were significantly associated with DFS and OS rates in NSCLC patients treated with radiation or chemoradiation therapy. The association was significant with a prior false-positive rate of 0.1. NSCLC patients with rs664143 G or rs189037A alleles were at increased risk of disease progression compared with the other SNP genotypes. These results were further confirmed by the subgroup analysis. These findings suggest that these two *ATM* variants are associated with the prognosis of NSCLC patients and determine the efficacy of radiation therapy.

Radiation therapy induces DNA damage and tumor cell death. Inactivating *ATM* gene mutations contribute to genomic instability by reducing the efficiency of DNA double-strand break repair in response to radiation. *ATM* protein also detects DNA damage or other abnormal DNA structures in response to radiations and initiates DNA damage repair response that may include cell cycle arrest or apoptosis \[[@r21]\]. *ATM* activates checkpoint kinase, which induces phosphorylation of CDC25 at Ser216 and inhibits the cell cycle progression by suppressing the activity of CDC25 and M-Cdk. ATM also regulates the activity of p53, a critical tumor suppressor protein in multiple ways. It mediates p53 phosphorylation through Chk2 kinase activation. Moreover, ATM phosphorylates Mdm2 proto-oncogene and prevents its binding to p53. Furthermore, activation of p53 induces the expression of p21, which blocks the cell cycle in the G1-S phase by inhibiting CDK activity \[[@r22], [@r23]\]. Therefore, inactivating mutations in the *ATM* gene can disrupt these critical cellular mechanisms. *ATM* inhibition enhances the sensitivity of cancer cells to radiation therapy \[[@r24], [@r25]\], whereas, phosphorylated ATM protein increases the radiation resistance of cancer cells and correlates with poor prognosis of cancer patients \[[@r26]\]. Considering the importance of *ATM* kinase in DNA damage repair, our data suggests that activating or inactivating *ATM* gene polymorphisms influence the efficacy of radiation therapy and the prognosis of NSCLC patients.

Previous studies have shown that *ATM* gene polymorphisms are associated with poor prognosis of patients with pancreatic cancer, acute myeloid leukemia, and colorectal cancer \[[@r27], [@r28], [@r29]\]. Su et al. performed a case-control study of 230 NSCLC patients and showed that *ATM* rs664143 was not associated with the treatment response of patients with advanced NSCLC \[[@r30]\]. However, they did not evaluate its relationship with the prognosis of NSCLC patients. Du et al. showed that *ATM* rs664143 A and rs664677 C alleles were associated with poor prognosis of 412 esophageal squamous cell carcinoma (ESCC) patients that received radiation or chemoradiation therapy \[[@r31]\]. In the present study, we demonstrate that NSCLC patients with the rs664143 A allele is associated with unfavorable prognosis after receiving radiation or chemoradiation therapy. One probable mechanism explaining these outcomes is inaccurate splicing when rs664143 is combined with an intronic splicing enhancer or repressor \[[@r32]\]. However, further investigation is required to ascertain the molecular mechanisms involved in the process. We also demonstrate that *ATM* rs189037 is associated with poor prognosis of NSCLC patients treated with radiation or chemoradiation therapy. This SNP is located in the promoter region of the *ATM* gene. A previous study showed that *ATM* rs189037 is associated with radiation- induced pneumonia in lung cancer patients \[[@r33]\], but, its role in survival outcomes of NSCLC patients has not been reported. In a previous study of breast cancer patients, those with *ATM* rs664677 TC genotype showed increased radiation resistance compared to the rs664677 TT genotype \[[@r34]\]. Furthermore, pancreatic cancer patients with the rs664677 TC genotype showed worse prognosis than those with the rs664677 TT genotype \[[@r28]\]. In advanced ESCC patients receiving radiation therapy, two *ATM* SNPs, rs664143, and rs664677, were associated with survival times \[[@r31]\]. In contrast, our study showed no correlation between rs664677 and prognosis of NSCLC patients that received radiation or chemoradiation therapy. The reasons for these contrasting findings are not clear and further studies are necessary to determine the differential function or role of rs664677 in different types of cancers.

One plausible explanation for our findings is that the two ATM SNPs (or haplotypes) modulate the function of the ATM protein. This determines the response of NSCLC cells to radiation and chemo-radiation therapy, which affects their survival and contributes to differential prognosis of patients with different *ATM* SNPs. ATM protein is a key regulator of cell cycle. Cell cycle is blocked under conditions of DNA damage, incomplete replication, or abnormal spindle formation. When normal cells are irradiated, DNA repair mechanisms are activated so that the DNA damage is rectified. Cell cycle inhibition of irradiated cells prevents the proliferation of malignant cells that contain genetic mutations. However, tumor cells are defective in cell cycle checkpoints and DNA repair mechanisms. This results in uncontrolled proliferation and differentiation of tumor cells with genetic mutations \[[@r35]\]. Mutations in the *ATM* gene alter the structure and function of the ATM protein in ataxia telangiectasia (A-T) patients. Therefore, A-T patient cells show aberrant cell cycle checkpoints and DNA damage repair, increased sensitivity to apoptosis, chromosomal instability, and radiation sensitivity. Moreover, the incidence of cancers is significantly higher in patients with heterozygous or homozygous *ATM* mutations compared to individuals with the wild-type *ATM* gene \[[@r36]\]. The rs189037 is located at the 5\'UTR of ATM gene (NC_000011.10: g. 108354934), and rs664143 is located at the intron of ATM gene (NC_000011.10: g.108354934). Two SNPs are very close loci (131bp) existing in two intros. We used the web-based tool (Improbizer, <https://users.soe.ucsc.edu/~kent/improbizer/improbizer.html>) to check the splicing effect of two sites, and the results suggested that two sited exist in protein-binding motifs have a potential as binding sites of intronic splicing enhancer, indicating a possibility that both sites may be related to splicing process to lead to inaccurate splicing. However, this hypothesis should be confirmed through further research.

Our study has several limitations. Firstly, our study includes NSCLC patients treated with radiation or chemoradiation, but does not investigate NSCLC patients that underwent surgery. Secondly, we adjusted the survival outcomes for a few common clinical parameters, but, more factors should be considered. Thirdly, we did not identify the mechanisms underlying the findings of our study. Finally, we did not perform haplotype analysis because only two significant SNPs were found.

In conclusion, our study demonstrates that *ATM* gene polymorphisms are significantly associated with disease progression and survival outcomes in NSCLC patients that have received radiation or chemoradiation therapy. These two *ATM* SNPs are potential prognostic biomarkers to predict survival outcomes of NSCLC patients that receive radiation or chemoradiation therapy.

MATERIALS AND METHODS
=====================

Study population
----------------

This two-center follow-up study was conducted at Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University and Tangshan People's Hospital from January 2009 to December 2017. The inclusion criteria were: (1) newly diagnosed Han Chinese NSCLC patients that were confirmed by biopsy with TNM stage IIIA--IIIB NCSLC tumors; (2) availability of follow-up clinical data, and (3) patients underwent radiotherapy or chemoradiotherapy. Patients that (1) underwent surgery or stereotactic ablative radiation therapy, and (2) with an history of lung cancer and recurrent disease, severe cardiovascular diseases, cerebral apoplexy, or depression were excluded from the study. Tumors were classified based on histology according to the World Health Organization system for NSCLC. The tumor staging was according to the revised American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC 7^th^ Edition). This study was approved by the Ethics Committee of Yantai Yuhuangding Hospital, the Affiliated Hospital of Qingdao University, and conducted in accordance with the World Medical Association Declaration of Helsinki. We obtained written informed consent from all study subjects.

Radiation therapy
-----------------

All patients underwent computed tomography (CT) scans of 5 mm slice thickness in a supine position with hands crossed before placing the forehead and thermoplastic body model fixation. The scans were performed from the mastoid process to the bottom of the lung and the images were transmitted over the network to a three-dimensional (3-D) treatment planning system. The target area delineation was according to ICRU50 and ICRU62 report guidelines. The gross tumor volume (GTV) was defined as the tumor volume seen below the lung window. The GTV node (GTVnd) was defined as a metastatic lymph node seen below the mediastinal window. The characteristics of the GTVnd were: short diameter \> LCM; multiple fusions; necrosis or envelope invasion; and confirmed by positron emission tomography (PET) or mediastinoscopy. For concurrent chemoradiotherapy or radiotherapy alone, the double-lung V20 was limited to \< 28% and \< 30%, respectively, and adjusted according to the patient's physical condition, age, complications, and basic lung-function parameters. The other tissue limits included a maximum dose of the spinal cord of \< 45 Gy, a cardiac V40 of \< 30%, and an esophageal V50 of \< 40--50%. A physician confirmed the treatment plan developed by the radiologist. The plan was further verified by calibration on the CT simulation positioning machine. Finally, the treatment was performed using a Vanaii linear accelerator.

Clinical data and follow-up
---------------------------

We obtained clinical data from the medical records of the patients for parameters such as age at treatment, gender, smoking, histologic type, TNM stage, treatment method, radiation technique, and radiation dose. The survival data was collected by follow-up through the telephone or from the outpatient medical records. The patients underwent physical examinations, CT or PET/CT, laboratory tests, and lung function evaluations at 6 weeks after therapy. The follow-up interval was every 3 months for 2 years, and 6 months thereafter. The primary follow-up outcome was overall survival (OS). OS was defined as the time period from the start of treatment to the last follow-up or death. We also evaluated disease-free survival (DFS), which was defined as the time period from the start of treatment until the date of the first local recurrence or metastasis at the last follow-up. Patients without progression were censored at the last follow-up date.

Selection and genotyping of *ATM* SNPs
--------------------------------------

We first searched for the *ATM* gene SNPs in the dbSNP database (<https://www.ncbi.nlm.nih.gov/snp/>) using a minor allele frequency of \> 5%. Next, we selected tagSNPs with r^2^ \> 0.8 among the Han Chinese population using the International HapMap project database and identified four SNPs (rs664143, rs664677, rs189037, and rs373759) with moderate linkage disequilibrium by analyzing the 1000GENOMES project database.

We obtained 5 mL of fasting venous blood in ethylenediaminetetraacetic acid (EDTA)-coated tubes and isolated the genomic DNA from peripheral blood leukocytes using the Biospin Whole Blood Genomic DNA Extraction Kit (Bioer Technology Co., Ltd., China) according to the manufacturer's instructions. The samples were stored at −20°C.

The SNP sequences were PCR amplified using primer sequences that were designed using Primer Premier 5.0, and synthesized by Sangon Biotech (Shanghai, China) as shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. The PCR protocol was: initial denaturation cycle at 95°C for 7 min; 35 cycles of denaturation at 95°C for 1 min, annealing at 56°C for 1 min, and extension at 72°C for 1 min; final extension cycle at 72°C for 10 min. The PCR products were separated by 2% agarose gel electrophoresis, purified by ExoSAP-IT (USB Corp., Cleveland, OH, USA), sequenced in an Applied Biosystems 3730xl automated sequencer (Applied Biosystems, Foster City, CA, USA), and analyzed using the Vector NTI software.

Statistical analysis
--------------------

The continuous variables were converted into categorical variables based on the mean age or median dose. The median OS and DFS were determined by Kaplan-Meir survival curve analyses using the log-rank test. The relationship between clinical parameters, *ATM* SNPs and survival parameters, OS and DFS, was determined using univariate and multivariate cox proportional hazards regression models. The multivariate Cox proportional regression model was adjusted for age, gender, smoking, histology, stage, treatment, radiation technique, and dose and the corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Subgroup analyses were performed for significant variables such as smoking, tumor stage, treatment, and radiation dose. The false-positive probability analysis was conducted by assuming that the HR for a risk allele was 1.5 and the HR for a protective allele was 1/1.5 times below the prior probability of 0.01 for each SNP. A significant association was defined as a false-positive value of \< 0.20. Statistical significance was defined as a two-sided P-value \< 0.05. Statistical analysis was performed using the SPSS 23.0 software.
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